Sociedad Americana de Hirudoterapia

Delayed-onset, persisting autoimmune heparin-induced thrombocytopenia with thrombosis following craniofacial surgery

Case report published in BMJ Case Reports (2026)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportEnsayos clínicosDesarrollo de fármacosWill VJ et al. · BMJ Case Reports, 2026

Abstract

We report a case of a patient who developed delayed-onset, persisting autoimmune heparin-induced thrombocytopenia (HIT) following prophylactic anticoagulation with unfractionated heparin (UFH) after surgical treatment of a complex midfacial and mandibular fracture. Four days after stopping prophylactic anticoagulation, the patient developed pulmonary embolism and mild thrombocytopenia. HIT was initially not suspected and therapeutic anticoagulation was started. The patient subsequently developed severe thrombocytopenia consistent with HIT. Despite cessation of UFH and initiation of argatroban, thrombocytopenia did not improve. A HIT-antibody immunoassay and functional assay (HIPA) was strongly positive, and HIPA showed activity even in the absence of heparin, supporting the diagnosis of delayed-onset, persisting autoimmune HIT (aHIT). The patient was treated with immunoglobulin, resulting in a rapid recovery of platelet counts. This case highlights the importance of early recognition and appropriate management of aHIT, especially in patients with persisting thrombocytopenia despite standard HIT therapy.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleCase Reports
Indexed MeSH termsHumansHeparinAnticoagulantsThrombocytopeniaPulmonary EmbolismMaleThrombosisPostoperative ComplicationsPurpura, Thrombocytopenic, IdiopathicFemaleMiddle Aged

Resumen

Delayed-onset autoimmune HIT (aHIT) following heparin prophylaxis after craniofacial fracture repair; HIPA assay was positive even without heparin, and only argatroban plus IVIG resulted in platelet count recovery.

Por qué esto importa para la hirudoterapia

This case report describes a patient who developed delayed-onset, persisting autoimmune heparin-induced thrombocytopenia (aHIT) with thrombosis following prophylactic unfractionated heparin after surgical treatment of a complex midfacial and mandibular fracture, with pulmonary embolism and severe thrombocytopenia developing despite cessation of UFH and initiation of argatroban. A strongly positive HIPA assay showing activity even in the absence of heparin supported the aHIT diagnosis, and treatment with immunoglobulin resulted in rapid platelet recovery. The article has no direct relevance to ASH's domain: the abstract makes no mention of hirudin, lepirudin, leeches, or any leech-derived therapy. CAVEAT: This is a single case report focused on autoimmune HIT pathogenesis and immunomodulatory treatment; it contains no leech-related content, and any connection to hirudotherapy or the leech secretome is absent.

Citación

Delayed-onset, persisting autoimmune heparin-induced thrombocytopenia with thrombosis following craniofacial surgery.

Will VJ et al. · BMJ Case Reports, 2026

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.